Expanding market share through minimally manipulated biologics technology in Saudi Arabia and UAE
[Munhwa News | Reporter Sunhye Park]
Korean biotech company REV-MED announced on the 4th that it is expanding its presence in the Middle Eastern market using its proprietary minimally manipulated biologic concentration kits. With high medical demand and purchasing power, countries like Saudi Arabia and the UAE have emerged as promising blue oceans for the global pharmaceutical and biotech industries.
REV-MED is rapidly increasing its market share in these regions through its flagship kits. Despite Saudi Arabia being known for its high regulatory barriers in healthcare, REV-MED has already proven its global capabilities with regulatory approvals from Japan (PMDA) and China (NMPA), further validating its entry into the Middle East.
The company is also actively engaging in scientific outreach and academic activities to highlight the efficacy and safety of its biologic products. Recently published papers have contributed to strengthening the scientific credibility of their technology and boosting trust in the global market.
An industry insider stated:
“The Middle East is rapidly emerging as a hub for both medical and aesthetic innovation, providing new opportunities for Korean biotech companies. REV-MED is expected to further strengthen its global competitiveness through its proprietary technologies.”
The Middle Eastern market is experiencing rapid growth not only in general healthcare but also in aesthetic medicine and regenerative therapies. According to research firm Research and Markets, the Middle East and Africa pharmaceutical market is expected to grow at an average annual rate of 6.10% by 2030. Meanwhile, Saudi Arabia’s cosmetic surgery market is projected to more than double by 2032.
Source: Munhwa News
Expanding market share through minimally manipulated biologics technology in Saudi Arabia and UAE
[Munhwa News | Reporter Sunhye Park]
Korean biotech company REV-MED announced on the 4th that it is expanding its presence in the Middle Eastern market using its proprietary minimally manipulated biologic concentration kits. With high medical demand and purchasing power, countries like Saudi Arabia and the UAE have emerged as promising blue oceans for the global pharmaceutical and biotech industries.
REV-MED is rapidly increasing its market share in these regions through its flagship kits. Despite Saudi Arabia being known for its high regulatory barriers in healthcare, REV-MED has already proven its global capabilities with regulatory approvals from Japan (PMDA) and China (NMPA), further validating its entry into the Middle East.
The company is also actively engaging in scientific outreach and academic activities to highlight the efficacy and safety of its biologic products. Recently published papers have contributed to strengthening the scientific credibility of their technology and boosting trust in the global market.
An industry insider stated:
“The Middle East is rapidly emerging as a hub for both medical and aesthetic innovation, providing new opportunities for Korean biotech companies. REV-MED is expected to further strengthen its global competitiveness through its proprietary technologies.”
The Middle Eastern market is experiencing rapid growth not only in general healthcare but also in aesthetic medicine and regenerative therapies. According to research firm Research and Markets, the Middle East and Africa pharmaceutical market is expected to grow at an average annual rate of 6.10% by 2030. Meanwhile, Saudi Arabia’s cosmetic surgery market is projected to more than double by 2032.
Source: Munhwa News